English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective. To evaluate effectiveness and safety of Fufang Kushen Injection combined with transcatheter arterial chemoembolization (TACE) for primary liver cancer (PLC). Search Strategy. Electronic databases were searched until 2 July, 2015. Inclusion Criteria. We included randomized clinical trials about comparison between Fufang Kushen Injection combined with TACE (FFKS-TACE) and TACE alone for treatment of PLC. Data Extraction and Analyses. Study selection, data extraction, quality assessment, and data analyses were conducted according to Cochrane standards. Results. 19 randomized trials were included. Methodological quality of the included trials was evaluated as generally low. compared with TACE alone, Meta-analysis showed that FFKS-TACE significantly improved the effective rate, KPS, six-month, one-year and two-year survival; significantly reduced the incidence of nausea and vomiting, fever, myelosuppression, transminase increased, bilirubin increased and stomach ache. Conclusion. FFKS-TACE for PLC can not only improve the effectiveness rate, KPS and survival rate, but also reduce the incidence rate of the clinical adverse effects such as nausea and vomiting, fever, myelosuppression, hepatic injury and stomach ache. However, the conclusion needs to be proved by further experiments on account of the absence of high quality articles. But evidence remains weak, rigorously designed trials are warranted to confirm these results.

Meta-Analysis of Randomized Controlled Trial in Treating Primary Liver Cancer by Fufang Kushen Injection Combined with TACE